Ann: Extension for Voluntary Suspension, page-36

It is quite ironic that at the time WP tweeted, back when, (?) was ‘cough, cough’ when RAP went down to 8 cents (?) on the failure of third parties to follow proper protocol in application of RAP IP.

Fast track to the future and the market cap of RAP is 171 mill, Admedus is .....

A lesson in being humble certainly would not go astray in the future.

It is most unfortunate, imo, that at this time much of the upside of Admedus has been discounted, so much so that this stock has to remain suspended to protect the sp.

Sentiment on RAP and AHZ is polar to each other, one company on the up and up, at this time, and the other on the ropes, despite some pretty ‘cutting edge’ IP.

Have no idea where this may end up, Eire suggested a deal on the TAVR (?) in the next six months, what happens in the interim?, my thoughts are that all dependent on the Adapt platform IP to ‘save’ the company in the immediate future.

TAVR deal; reminiscent of the Vacc story, there was no partner, tonne of funds up in vapour, via CRs, will market sentiment on resume of trading acknowledge a pending TAVR deal?, if on the best case scenario of immediate funds that are non-dilutive??

TAVR IP; lack of market acknowledgement, may also impact on the company’s prospects, despite growing revenue as in may inhibit cash flow positive as funds negated by costs of R&D for TAVR, ground hog day or not?

TAVR deal on opening of trading, will be a rainmaker of a deal, all forward from there, anything less will make it a lot harder.